Health
India Latest News: Top National Headlines Today & Breaking News | The Hindu

Hyderabad doctor brings down rare disease drug cost by ₹6.5 lakh; seven children to get free treatment

Source Entity

India Latest News: Top National Headlines Today & Breaking News | The Hindu

November 21, 2026
Hyderabad doctor brings down rare disease drug cost by ₹6.5 lakh; seven children to get free treatment

A Hyderabad-based pediatrician has successfully reduced the treatment cost for seven children suffering from the rare Allan-Herndon-Dudley syndrome. By utilizing pharmaceutical compounding in the Netherlands, the cost was lowered from ₹9 crore to ₹2.5 lakh, enabling free access for these families.

A Breakthrough in Rare Disease Treatment

In a landmark development for pediatric medicine in India, a group of seven children diagnosed with the rare genetic disorder Allan-Herndon-Dudley syndrome (AHDS) are set to receive life-changing treatment. On November 30, these families will be provided with a full year's supply of the medication tiratricol at no cost. This initiative, spearheaded by Hyderabad-based pediatrician Dr. Sivaranjani Santosh in collaboration with Access to Medicines India, represents a significant victory against the prohibitive financial barriers often associated with orphan drugs.

The Financial Barrier of Rare Disorders

The challenge of treating AHDS is fundamentally economic. For many families, the commercial version of the necessary medication can cost as much as ₹9 crore per year, a sum that renders treatment inaccessible for the vast majority of patients. This disparity highlights the systemic issues within the global pharmaceutical market, where low-volume, high-cost drugs for rare diseases are often priced beyond the reach of those who need them most, leaving families in a state of medical helplessness.

Pharmaceutical Compounding as a Solution

The core of this success story lies in the strategic use of pharmaceutical compounding. By partnering with international experts in the Netherlands, Dr. Santosh and her team were able to create a compounded version of tiratricol that costs approximately ₹2.5 lakh per child annually. This drastic reduction—from crores to lakhs—demonstrates that the exorbitant price tags on certain rare disease medications are not always reflective of production costs, but rather of market dynamics and regulatory hurdles.

Implications for Healthcare Accessibility

This initiative serves as a replicable model for improving healthcare accessibility in developing nations. By bypassing traditional, high-cost commercial supply chains and utilizing legal, safe compounding methods, medical professionals can provide essential therapy for rare conditions. This approach not only provides immediate relief to the seven families involved but also sets a precedent for how patient advocacy groups and dedicated clinicians can navigate the complex landscape of international drug procurement.

Future Trends and Challenges

While this event is a cause for celebration, it also underscores the urgent need for a more sustainable policy framework regarding rare disease management in India. Relying on individual initiatives and international compounding is an effective stop-gap, but long-term success will require domestic policy support, increased investment in rare disease research, and simplified regulatory pathways for importing or locally manufacturing essential orphan drugs.

Conclusion

The initiative led by Dr. Sivaranjani Santosh serves as a powerful reminder of the impact of medical innovation combined with social advocacy. By successfully reducing the cost of tiratricol, this project has not only saved lives but has also brought the issue of rare disease affordability to the forefront of the public health conversation in India. It is a testament to the fact that when clinical expertise meets systemic problem-solving, the barriers to essential care can be dismantled.

Verification Required?

Read the full report from the primary source

Go to India Latest News: Top National Headlines Today & Breaking News | The Hindu